Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, Yoshida R, Hirosue A, Ogi H, Hiraki A, Jono H, Hamada A, Yoshida K, Nishimura Y, Nakamura Y, Shinohara M. Yoshitake Y, et al. Among authors: hirayama m. Clin Cancer Res. 2015 Jan 15;21(2):312-21. doi: 10.1158/1078-0432.CCR-14-0202. Epub 2014 Nov 12. Clin Cancer Res. 2015. PMID: 25391695 Clinical Trial.
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Irie A, Kawahara K, Yatsuda J, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Tomita Y, et al. Among authors: hirayama m. Clin Cancer Res. 2013 Aug 15;19(16):4508-20. doi: 10.1158/1078-0432.CCR-13-0197. Epub 2013 May 28. Clin Cancer Res. 2013. PMID: 23714729
Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
Tomita Y, Yuno A, Tsukamoto H, Senju S, Yoshimura S, Osawa R, Kuroda Y, Hirayama M, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Tomita Y, et al. Among authors: hirayama m. Int J Cancer. 2014 Jan 15;134(2):352-66. doi: 10.1002/ijc.28376. Int J Cancer. 2014. PMID: 24734272
Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease.
Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Tomita Y, et al. Among authors: hirayama m. Oncoimmunology. 2014 Mar 27;3:e28100. doi: 10.4161/onci.28100. eCollection 2014. Oncoimmunology. 2014. PMID: 25340007 Free PMC article.
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.
Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y. Hirayama M, et al. Oncoimmunology. 2016 Jan 4;5(6):e1123368. doi: 10.1080/2162402X.2015.1123368. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471607 Free PMC article.
Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia.
Sakata J, Yoshida R, Matsuoka Y, Nagata M, Hirosue A, Kawahara K, Nakamura T, Nakamoto M, Hirayama M, Takahashi N, Nakashima H, Arita H, Ogi H, Hiraki A, Shinohara M, Nakayama H. Sakata J, et al. Among authors: hirayama m. Cancer Med. 2017 Apr;6(4):730-738. doi: 10.1002/cam4.1005. Epub 2017 Mar 3. Cancer Med. 2017. PMID: 28256094 Free PMC article.
Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity score matching method.
Yoshida R, Nagata M, Hirosue A, Kawahara K, Nakamoto M, Hirayama M, Takahashi N, Matsuoka Y, Sakata J, Nakashima H, Arita H, Hiraki A, Shinohara M, Kikuchi K, Nakayama H. Yoshida R, et al. Among authors: hirayama m. PLoS One. 2020 Apr 15;15(4):e0231656. doi: 10.1371/journal.pone.0231656. eCollection 2020. PLoS One. 2020. PMID: 32294127 Free PMC article.
The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation.
Matsuoka Y, Yoshida R, Kawahara K, Sakata J, Arita H, Nkashima H, Takahashi N, Hirayama M, Nagata M, Hirosue A, Kuwahara Y, Fukumoto M, Toya R, Murakami R, Nakayama H. Matsuoka Y, et al. Among authors: hirayama m. Lab Invest. 2022 Aug;102(8):896-907. doi: 10.1038/s41374-022-00776-w. Epub 2022 Apr 12. Lab Invest. 2022. PMID: 35414650 Free PMC article.
916 results